The rollout of the coronavirus vaccine developed by Johnson & Johnson in Europe has been delayed, following a move in the US to immediately pause use of the jab while reports of blood clots are investigated.

Johnson & Johnson, which operates under the name of its Belgian subsidiary Janssen for its one-dose vaccine in the UK and Europe, said on 13 April it had “made the decision to proactively delay the rollout of our vaccine in Europe”.